La vendita allo scoperto per Surgery Partners dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Surgery Partners. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Surgery Partners (NASDAQ:SGRY) Azioni, Report sulle vendite allo scoperto

SURGERY PARTNERS INC

Surgery Partners

Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earns revenues from contracts with patients in which the performance obligations are to provide health care services.

Surgery Partners Inc

Jefferies analyst Stephanie Moore maintains Hertz Global Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) with a Hold and lowers the price target from $7 to $6.

News

Price Target

Analyst Ratings

Jefferies Maintains Hold on Hertz Global Holdings, Lowers Price Target to $6

Needham analyst Serge Belanger reiterates Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) from Hold to Hold.

Reiteration

VRCA

Needham Reiterates Hold on Verrica Pharmaceuticalsto Hold

<a href="https://www.bloomberg.com/news/articles/2025-05-14/us-is-not-negotiating-for-weaker-dollar-as-part-of-tariff-talks">https://www.bloomberg.com/news/articles/2025-05-14/us-is-not-negotiating-for-weaker-dollar-as-part-of-tariff-talks</a>
&nbsp;

Macro Economic Events

Global

Economics

PowerShares DB US Dollar Index Bullish Fund

'U.S. Not Seeking To Weaken Dollar As Part Of Trade Deals' - Bloomberg

Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) CEO Brian Armstrong has called on Department of Government Efficiency contractors to apply to Coinbase to &#8220;help create a more efficient financial system for the world.&#8221;
What Happened: In a <a href="https://x.com/brian_armstrong/status/1922368587626643618">post</a> on X on May 13, Armstrong wrote &#8220;If you&#8217;re looking for your next mission to serve your country, consider taking the DOGE Staff interview, help us build a more efficient financial system for the world at Coinbase.&#8221;
He reposted a video featuring a Harvard dropout who joined the DOGE team, saying he found greater impact and purpose working on financial reform than in academia. 
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45323509/coinbase-analysts-look-ahead-to-q2-after-disappointing-q1-higher-crypto-prices-increased-volumes">Coinbase Analysts Look Ahead To Q2 After Disappointing Q1: &#8216;Higher Crypto Prices… Increased Volumes&#8217;</a>
Why It Matters: Armstrong has long <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42035165/coinbase-ceo-brian-armstrong-says-doge-department-is-a-once-in-a-lifetime-opprtunity-advocates-abolishing-individual-income-tax">championed</a> DOGE as a vehicle for financial reform, previously describing it as a "once-in-a-lifetime opportunity" to expand economic freedom in the U.S. 
In November 2024, he even proposed replacing individual income tax with corporate taxation, highlighting DOGE's role in broader policy innovation.
More recently, in May 2025, Armstrong <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45309227/coinbase-ceo-brian-armstrong-believes-traditional-banks-launching-own-stablecoins-not-necessarily-the-best-path-pitches-usdc-as-option">noted</a> that stablecoins like USDC have strong network effects and urged banks to partner with existing players rather than creating their own.
In February 2025, Armstrong <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43591727/coinbase-ceo-brian-armstrong-says-bitcoin-adoption-to-reach-billions-by-2030">likened</a> Bitcoin adoption to the early days of mobile phones and the internet, predicting billions of global users by 2030.
As Coinbase gains momentum, including its inclusion in the S&amp;P 500 Index, Armstrong's DOGE initiative may signal a deeper push toward financial system disruption from within the industry's top leadership.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45368175/cathie-wood-says-index-sensitive-managers-will-be-compelled-to-consider-coinbase-as-crypto-exchange-platform-joins-sp-500-index">Cathie Wood Says &#8216;Index-Sensitive Managers Will Be Compelled to Consider&#8217; Coinbase As Crypto Exchange Platform Joins S&amp;P 500 Index</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

COIN

Coinbase CEO Brian Armstrong Invites DOGE Staff To 'Create A More Efficient Financial System'

Applied Industrial Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>) has outperformed the market over the past 20 years by 4.63% on an annualized basis producing an average annual return of 12.91%. Currently, Applied Industrial Techs has a market capitalization of $8.91 billion. 
Buying $100 In AIT: If an investor had bought $100 of AIT stock 20 years ago, it would be worth $1,157.94 today based on a price of $232.10 for AIT at the time of writing.
<h3>Applied Industrial Techs's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747241213_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

HC Wainwright &amp; Co. analyst Scott Buck reiterates Mogo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOGO#NASDAQ">MOGO</a>) with a Buy and maintains $4 price target.

MOGO

HC Wainwright & Co. Reiterates Buy on Mogo, Maintains $4 Price Target

HC Wainwright &amp; Co. analyst Kevin Dede downgrades WonderFi Techs (TSX:<a class="ticker" href="https://www.benzinga.com/stock/WNDR#TSX">WNDR</a>) from Buy to Neutral.

Downgrades

TSX:WNDR

HC Wainwright & Co. Downgrades WonderFi Techs to Neutral

WIIM

Sanofi share are trading lower after the company announced plans to invest at least $20 billion in the US through 2030.

PONY

Pony AI shares are trading lower. CNBC reported that one of the company's robotaxis caught fire.

Sanofi today announces its intention to invest at least $20 billion in the United States through 2030. The expected investment includes a significant increase in research and development spending and the allocation of billions of dollars to US manufacturing.
The announcement comes as Sanofi prepares for the potential launch of numerous new first- or best-in-class medicines across many indications in the coming years, aiming to improve the health of countless Americans. Work being done within the United States by Sanofi and by the hundreds of companies it supports is anticipated to contribute to job creation and innovation in numerous communities that are home to Sanofi and its partners, while also helping to enhance the US supply chain.

Sanofi Intends To Invest At Least $20B In US Through 2030, Growing Investments In Science And Expanding Domestic Manufacturing

ARAI

Arrive AI Receives Approval To List Its Shares On Nasdaq Under Symbol ARAI; To Begin Trading On May 15, 2025

Needham analyst Ryan Koontz reiterates Planet Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) with a Buy and maintains $8 price target.

Needham Reiterates Buy on Planet Labs, Maintains $8 Price Target

V2X Collaborates With Bell Textron To Begin Strategic Planning For U.S. Army's Flight School Next Program

Fidelity National Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNF#NYSE">FNF</a>) has outperformed the market over the past 5 years by 1.87% on an annualized basis producing an average annual return of 16.9%. Currently, Fidelity National Finl has a market capitalization of $15.60 billion. 
Buying $100 In FNF: If an investor had bought $100 of FNF stock 5 years ago, it would be worth $215.81 today based on a price of $56.79 for FNF at the time of writing.
<h3>Fidelity National Finl's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747240311_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Fidelity National Finl 5 Years Ago Would Be Worth Today

VRTX

Live On CNBC, Steve Weiss Announces Sold Vertex Pharmaceuticals

Keefe, Bruyette &amp; Woods analyst Sanjay Sakhrani maintains Nayax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYAX#NASDAQ">NYAX</a>) with a Market Perform and raises the price target from $38 to $40.

NYAX

Keefe, Bruyette & Woods Maintains Market Perform on Nayax, Raises Price Target to $40

Live On CNBC, Steve Weiss Announces Bought More UnitedHealth Group

<a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pheochromocytoma-or-paraganglioma#:~:text=On%20May%2014%2C%202025%2C%20the,an%20oral%20therapy%20for%20PPGL" title="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pheochromocytoma-or-paraganglioma#:~:text=On%20May%2014%2C%202025%2C%20the,an%20oral%20therapy%20for%20PPGL">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pheochromocytoma-or-paraganglioma#:~:text=On%20May%2014%2C%202025%2C%20the,an%20oral%20therapy%20for%20PPGL</a>.

Biotech

General

Reported Earlier: 'FDA Approves Belzutifan For Pheochromocytoma Or Paraganglioma' - FDA

BMO Capital analyst Simeon Siegel maintains Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) with a Outperform and lowers the price target from $12 to $9.

Comments

Surgery Partners

Vendite allo scoperto

Surgery Partners (NASDAQ:SGRY) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO